Minerva Neurosciences: Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
BURLINGTON, Mass., Feb. 25, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business...
Read full article »
Minerva Neurosciences develops and commercializes clinical-stage products for the treatment of central nervous system diseases.
Read more